1. Home
  2. CCM vs PLUR Comparison

CCM vs PLUR Comparison

Compare CCM & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concord Medical Services Holdings Limited

CCM

Concord Medical Services Holdings Limited

HOLD

Current Price

$4.69

Market Cap

21.3M

Sector

Health Care

ML Signal

HOLD

Logo Pluri Inc.

PLUR

Pluri Inc.

HOLD

Current Price

$1.40

Market Cap

18.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCM
PLUR
Founded
1997
2001
Country
China
Israel
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3M
18.5M
IPO Year
2009
2001

Fundamental Metrics

Financial Performance
Metric
CCM
PLUR
Price
$4.69
$1.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
74.4K
22.8K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.78
EPS
N/A
N/A
Revenue
N/A
$1,336,000.00
Revenue This Year
N/A
$97.38
Revenue Next Year
N/A
$293.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
309.82
52 Week Low
$3.18
$1.38
52 Week High
$6.98
$5.17

Technical Indicators

Market Signals
Indicator
CCM
PLUR
Relative Strength Index (RSI) 46.98 35.57
Support Level $4.41 N/A
Resistance Level $5.43 $1.85
Average True Range (ATR) 0.41 0.12
MACD -0.05 -0.01
Stochastic Oscillator 17.12 4.35

Price Performance

Historical Comparison
CCM
PLUR

About CCM Concord Medical Services Holdings Limited

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: